| Author, Center | Study Design | Organ | rATG Regimen | Control |
| Brennan, Barnes-Jewish, Wash U [3] | Prospective, Randomized, Double-blinded | K | 1.5 mg/kg 7days, total 10.5 mg/kg () | Atgam 15 mg/kg 7d() | Agha, Barnes-Jewish, Wash U [4] | Prospective, Nonrandomized | K | 3.0 mg/kg/day, then 1.5 mg/kg 2 days, total 6 mg/kg () | 1.5 mg/kg 7d, total 10.5 mg/kg() | Peddi, U of Cincinnati [5] | Prospective, Single-group | High risk K, KP | 1.5 mg/kg, Intermittent dosing, based on CD3+ monitoring, mean total 4.2 mg/kg () | Uncontrolled | Starzl, Pittsburg[6] | Prospective, Single-group | K, P, L | ~5 mg/kg 1 dose, total 5 mg/kg () | Uncontrolled | Stratta, Wake Forest [7] | Retrospective, Single group | P | 1.5 mg/kg, Alternate-day therapy until calcineurin inhibitor levels are achieved, mean total 5.4 mg/kg () | Uncontrolled | Wong, Massachusetts General Hospital [8] | Prospective | K | 1.0 mg/kg 3 day, total 3 mg/kg () | 1.5 mg/kg 3 d, total 4.5 mg/kg () | Gurk, U of Maryland [9] | Retrospective cohort | High risk K | Target 1.5 mg/kg 7-10day< 7.5 mg/kg () | >7.5 mg/ kg () | Stevens, U of Nebraska [10] | Prospective, Randomized | K | 6 mg/kg 1 dose () | 1.5 mg/kg qod 4 doses, total dose 6 mg/kg () |
|
|